The gut microbiome and type 2 diabetes status in the Multiethnic Cohort.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
11
2020
accepted:
15
04
2021
entrez:
23
6
2021
pubmed:
24
6
2021
medline:
28
10
2021
Statut:
epublish
Résumé
The gut microbiome may play a role in inflammation associated with type 2 diabetes (T2D) development. This cross-sectional study examined its relation with glycemic status within a subset of the Multiethnic Cohort (MEC) and estimated the association of circulating bacterial endotoxin (measured as plasma lipopolysaccharide-binding protein (LBP)) with T2D, which may be mediated by C-reactive protein (CRP). In 2013-16, cohort members from five ethnic groups completed clinic visits, questionnaires, and stool and blood collections. Participants with self-reported T2D and/or taking medication were considered T2D cases. Those with fasting glucose >125 and 100-125 mg/dL were classified as undiagnosed (UT2D) and pre-diabetes (PT2D) cases, respectively. We characterized the gut microbiome through 16S rRNA gene sequencing and measured plasma LBP and CRP by standard assays. Linear regression was applied to estimate associations of the gut microbiome community structure and LBP with T2D status adjusting for relevant confounders. Among 1,702 participants (59.9-77.4 years), 735 (43%) were normoglycemic (NG), 506 (30%) PT2D, 154 (9%) UT2D, and 307 (18%) T2D. The Shannon diversity index decreased (ptrend = 0.05), while endotoxin, measured as LBP, increased (ptrend = 0.0003) from NG to T2D. Of 10 phyla, Actinobacteria (ptrend = 0.007), Firmicutes (ptrend = 0.003), and Synergistetes (ptrend = 0.02) were inversely associated and Lentisphaerae (ptrend = 0.01) was positively associated with T2D status. Clostridium sensu stricto 1, Lachnospira, and Peptostreptococcaceae were less, while Escherichia-Shigella and Lachnospiraceae were more abundant among T2D patients, but the associations with Actinobacteria, Clostridium sensu stricto 1, and Escherichia-Shigella may be due metformin use. PT2D/UT2D values were closer to NG than T2D. No indication was detected that CRP mediated the association of LBP with T2D. T2D but not PT2D/UT2D status was associated with lower abundance of SCFA-producing genera and a higher abundance of gram-negative endotoxin-producing bacteria suggesting that the gut microbiome may contribute to chronic systemic inflammation and T2D through bacterial translocation.
Sections du résumé
BACKGROUND
The gut microbiome may play a role in inflammation associated with type 2 diabetes (T2D) development. This cross-sectional study examined its relation with glycemic status within a subset of the Multiethnic Cohort (MEC) and estimated the association of circulating bacterial endotoxin (measured as plasma lipopolysaccharide-binding protein (LBP)) with T2D, which may be mediated by C-reactive protein (CRP).
METHODS
In 2013-16, cohort members from five ethnic groups completed clinic visits, questionnaires, and stool and blood collections. Participants with self-reported T2D and/or taking medication were considered T2D cases. Those with fasting glucose >125 and 100-125 mg/dL were classified as undiagnosed (UT2D) and pre-diabetes (PT2D) cases, respectively. We characterized the gut microbiome through 16S rRNA gene sequencing and measured plasma LBP and CRP by standard assays. Linear regression was applied to estimate associations of the gut microbiome community structure and LBP with T2D status adjusting for relevant confounders.
RESULTS
Among 1,702 participants (59.9-77.4 years), 735 (43%) were normoglycemic (NG), 506 (30%) PT2D, 154 (9%) UT2D, and 307 (18%) T2D. The Shannon diversity index decreased (ptrend = 0.05), while endotoxin, measured as LBP, increased (ptrend = 0.0003) from NG to T2D. Of 10 phyla, Actinobacteria (ptrend = 0.007), Firmicutes (ptrend = 0.003), and Synergistetes (ptrend = 0.02) were inversely associated and Lentisphaerae (ptrend = 0.01) was positively associated with T2D status. Clostridium sensu stricto 1, Lachnospira, and Peptostreptococcaceae were less, while Escherichia-Shigella and Lachnospiraceae were more abundant among T2D patients, but the associations with Actinobacteria, Clostridium sensu stricto 1, and Escherichia-Shigella may be due metformin use. PT2D/UT2D values were closer to NG than T2D. No indication was detected that CRP mediated the association of LBP with T2D.
CONCLUSIONS
T2D but not PT2D/UT2D status was associated with lower abundance of SCFA-producing genera and a higher abundance of gram-negative endotoxin-producing bacteria suggesting that the gut microbiome may contribute to chronic systemic inflammation and T2D through bacterial translocation.
Identifiants
pubmed: 34161346
doi: 10.1371/journal.pone.0250855
pii: PONE-D-20-34897
pmc: PMC8221508
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Metformin
9100L32L2N
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0250855Subventions
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL140335
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001855
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000130
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA071789
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA164973
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
mBio. 2014 Apr 22;5(2):e00889
pubmed: 24757212
Diabetes. 2004 Mar;53(3):693-700
pubmed: 14988254
Front Pharmacol. 2018 Jul 16;9:761
pubmed: 30061832
J Anim Sci. 2012 Dec;90 Suppl 4:266-8
pubmed: 23365351
Cell Metab. 2015 Aug 4;22(2):320-31
pubmed: 26244934
J Lipid Res. 2012 May;53(5):973-978
pubmed: 22394503
Diabetes. 2010 Jan;59(1):172-81
pubmed: 19794059
Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):966-973
pubmed: 32132150
J Nutr. 2017 Jul;147(7):1468S-1475S
pubmed: 28615382
Cell Host Microbe. 2015 May 13;17(5):662-71
pubmed: 25865369
Methods Enzymol. 2013;531:371-444
pubmed: 24060131
Bioresour Technol. 2018 Apr;253:343-354
pubmed: 29329775
Gut. 2021 Mar;70(3):499-510
pubmed: 32536605
Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):154-162
pubmed: 30206059
Diabetes Care. 2014 Aug;37(8):2343-50
pubmed: 24824547
Gut. 2013 Aug;62(8):1112-21
pubmed: 23135760
Gastroenterology. 2019 Mar;156(4):966-975.e10
pubmed: 30445012
Endocrine. 2019 Dec;66(3):485-493
pubmed: 31410749
J Lipid Res. 2006 Feb;47(2):241-59
pubmed: 16299351
PLoS One. 2013 Aug 27;8(8):e71108
pubmed: 24013136
Br J Nutr. 2017 Aug;118(4):312-320
pubmed: 28875870
Diabetes. 2016 Aug;65(8):2214-23
pubmed: 27217482
J Clin Endocrinol Metab. 2016 Apr;101(4):1445-54
pubmed: 26938201
Front Microbiol. 2017 Nov 15;8:2224
pubmed: 29187837
Nature. 2015 Dec 10;528(7581):262-266
pubmed: 26633628
Curr Microbiol. 2010 Jul;61(1):69-78
pubmed: 20087741
Diabetes Care. 2016 Feb;39(2):187-9
pubmed: 26798149
J Nutr. 2015 Dec;145(12):2774-80
pubmed: 26491121
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
Int J Obes (Lond). 2015 Oct;39(10):1531-8
pubmed: 26121961
Dig Dis Sci. 2020 Mar;65(3):840-851
pubmed: 32006211
Br J Nutr. 2016 Dec;116(11):1869-1877
pubmed: 27974055
Microb Ecol Health Dis. 2014 Jun 03;25:
pubmed: 24936169
Microorganisms. 2020 Jan 10;8(1):
pubmed: 31936722
Nature. 2012 Oct 4;490(7418):55-60
pubmed: 23023125
J Anim Sci Biotechnol. 2020 Feb 20;11:24
pubmed: 32099648
Genome Med. 2016 Apr 20;8(1):42
pubmed: 27098727
PLoS One. 2019 Dec 31;14(12):e0226372
pubmed: 31891582
Am J Clin Nutr. 2015 Mar;101(3):587-97
pubmed: 25733644
Diabetes. 2007 Jul;56(7):1761-72
pubmed: 17456850
mSystems. 2020 Mar 31;5(2):
pubmed: 32234773
Am J Epidemiol. 2000 Feb 15;151(4):346-57
pubmed: 10695593
J Clin Microbiol. 2006 Sep;44(9):3313-7
pubmed: 16954266
J Diabetes Obes. 2015 Dec 26;2(3):1-7
pubmed: 26756039
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
Int J Epidemiol. 2012 Apr;41(2):514-20
pubmed: 22253321
Nat Rev Gastroenterol Hepatol. 2016 Dec;13(12):691-706
pubmed: 27848961
Bioinformatics. 2010 Jan 15;26(2):266-7
pubmed: 19914921
Front Cell Infect Microbiol. 2020 Feb 25;10:63
pubmed: 32158702
Diabetologia. 2017 Jun;60(6):943-951
pubmed: 28434033
Nat Med. 2017 Jul;23(7):850-858
pubmed: 28530702
Cell Host Microbe. 2019 Aug 14;26(2):252-264.e10
pubmed: 31399369
Sci Rep. 2016 Sep 29;6:34360
pubmed: 27681607
Biochem J. 2000 Jun 15;348 Pt 3:607-14
pubmed: 10839993
Nat Biotechnol. 2013 Sep;31(9):814-21
pubmed: 23975157
PLoS One. 2014 Apr 10;9(4):e94249
pubmed: 24722003
Diabetologia. 2009 Sep;52(9):1766-77
pubmed: 19572116
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
J Nutr. 2020 Apr 1;150(4):861-872
pubmed: 31851320
Appl Environ Microbiol. 2002 Oct;68(10):5186-90
pubmed: 12324374
PLoS One. 2010 Feb 05;5(2):e9085
pubmed: 20140211
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
Nature. 2013 Jun 6;498(7452):99-103
pubmed: 23719380
ISME J. 2018 Jun;12(7):1631-1641
pubmed: 29434315
Clin Sci (Lond). 2018 Jun 12;132(11):1155-1168
pubmed: 29540537
NAR Genom Bioinform. 2020 Sep;2(3):lqaa078
pubmed: 33015620